Future investigations designed to determine the conditions in which rcasIL-10R1 would block IL-10 in vivo in a wider context will be of great scientific interest, and could be applied to induce a Th1 immune response in the development of vaccines and immunotherapeutic protocols against chronic infection and cancer in dogs. This evidence concerns the gene IL10 and cancer.